Business Context and Reporting Period
This Form 6-K was filed by NLS Pharmaceutics Ltd., a Swiss foreign private issuer, for March 2024 and dated March 11, 2024. The filing states that the company issued a press release titled “Nasdaq Accepts NLS Pharmaceutics’ Plan to Regain Listing Compliance.”
The request metadata identifies the company as Newcelx Ltd.; however, the filing itself identifies the registrant as NLS Pharmaceutics Ltd. The filing does not provide operating or financial results for the period.
Financial and Operating Metrics
- Revenue, profit, cash flow, margins, debt, liquidity, and other financial metrics: not provided in the filing text.
- The filing furnishes the Nasdaq compliance press release as Exhibit 99.1, but the press release content is not included in the supplied text.
Material Changes, Guidance, and Risks
- Nasdaq accepted the registrant’s plan to regain listing compliance.
- The filing does not state the specific Nasdaq deficiency, the remediation steps, the deadline, or the conditions for regaining compliance.
- No financial guidance, business outlook, management commentary, contingencies, or unusual financial items are provided in the supplied filing text.
- The report is incorporated by reference into specified Form F-3 registration statements, subject to later filings or reports superseding it.
Investor Verification Items
- Obtain and review Exhibit 99.1 for the full Nasdaq compliance plan, deadlines, and conditions.
- Confirm whether Nasdaq ultimately determined that the company regained listing compliance.
- Review subsequent SEC filings for financial results, liquidity, financing needs, and any additional Nasdaq actions.
- Confirm the registrant identity, given the discrepancy between the request metadata and the filing’s identification of NLS Pharmaceutics Ltd.